Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
For maximum microbiome impact, consider a two-phase approach
As of 2025, most large employers did not cover GLP-1 drugs for weight loss
2027 (The Triple-Hormone Peak): This looks like the "Year of Eli Lilly." Their triple-action Retatrutide (GIP + GLP-1 + Glucagon) is targeting a launch, alongside Boehringer Ingelheims Survodutide
If hormones, inflammation, recovery, or other metabolic factors are affecting progress, your provider may recommend a more comprehensive strategy to better support results
US$ 20.43
US$ 20.83
US$ 29.47
US$ 22.50
US$ 24.60
